Nuvation Bio Inc.
NUVBHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Nuvation Bio Inc. focuses on Biotechnology services and products. Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. At a $2.02B market cap, Nuvation Bio Inc. ranks as a mid-cap company within healthcare. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer.
Market Cap
$2.02B
Beta
1.53
P/E (TTM)
—
P/E (Fwd)
-96.67
EPS (TTM)
$-0.43
EPS (Fwd)
$-0.06
ROE
-39.5%
ROA
-17.0%
Cash
$533.7M
Total Debt
$217.0M
Free CF
-$100.0M
52W Change
152.2%
Annual Financials
Cash vs Debt
Nuvation Bio Inc. holds $533.7M in cash against $217.0M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$100.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -39.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
A beta of 1.53 means NUVB is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. With cash comfortably exceeding debt, NUVB has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Nuvation Bio Inc.'s trajectory.